Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.
about
Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining ConditionsWhat happens to cardiovascular system behind the undetectable level of HIV viremia?Cardiovascular disease in human immunodeficiency virus infected patients: A true or perceived risk?Metabolic syndrome, diabetes, and cardiovascular risk in HIVHIV infection and cardiovascular diseaseHIV infection and the risk of acute myocardial infarction.Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010Cardiovascular Complications of HIV-Associated Immune DysfunctionAn inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitorsAtherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.Effects of Therapy with Maraviroc on the Carotid Intima Media Thickness in HIV-1/HCV Co-infected Patients.A pilot study of brisk walking in sedentary combination antiretroviral treatement (cART)- treated patients: benefit on soluble and cell inflammatory markers.Resveratrol Co-Treatment Attenuates the Effects of HIV Protease Inhibitors on Rat Body Weight and Enhances Cardiac Mitochondrial Respiration.Enhanced effector function of CD8(+) T cells from healthy controls and HIV-infected patients occurs through thrombin activation of protease-activated receptor 1.Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.Aggregate risk of cardiovascular disease among adolescents perinatally infected with the human immunodeficiency virus.An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study.Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL) and Data Collection on Adverse Events ofCardiovascular disease risk among Chinese antiretroviral-naïve adults with advanced HIV disease.High correlation between Framingham equations with BMI and with lipids to estimate cardiovascular risks score at baseline in HIV-infected adults in the Temprano trial, ANRS 12136 in Côte d'Ivoire.Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals.Menthol cigarettes and the cardiovascular risks of people living with HIV.Pharmacologic boosting of atazanavir in maintenance HIV-1 therapy: the COREYA propensity-score adjusted studyAssociation of residual plasma viremia and intima-media thickness in antiretroviral-treated patients with controlled human immunodeficiency virus infectionHIV, vascular and aging injuries in the brain of clinically stable HIV-infected adults: a (1)H MRS study.HIV-associated neurocognitive disorder in Australia: a case of a high-functioning and optimally treated cohort and implications for international neuroHIV researchRates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*).Silent ischemic heart disease and pericardial fat volume in HIV-infected patients: a case-control myocardial perfusion scintigraphy study.Cardiovascular disease risk in an aging HIV population: not just a question of biology.Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialPlasma lipidomic profiling of treated HIV-positive individuals and the implications for cardiovascular risk prediction.Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapyEpidemiology and management of antiretroviral-associated cardiovascular disease.Clinical outcomes of a combined HIV and renal clinic.Management of dyslipidemia in HIV-infected patients.Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study.The Additive Value of Femoral Ultrasound for Subclinical Atherosclerosis Assessment in a Single Center Cohort of 962 Adults, Including High Risk Patients with Rheumatoid Arthritis, Human Immunodeficiency Virus Infection and Type 2 Diabetes MellitusNovel Biomarkers of Cardiac Stress, Cardiovascular Dysfunction, and Outcomes in HIV-Infected Individuals.Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population.Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.
P2860
Q26740117-F1F019A3-75C1-4026-9522-611EF22260D8Q26749024-6C12248C-FCC1-4A13-A10C-36521A3DA2C4Q26777866-FFDFFA22-D615-465D-AE03-3DD2A50B36ACQ26853470-5C8E9FB0-27A7-448F-9843-048A801F76CAQ27008915-EB402E59-DDA5-4387-AB95-50C8D70DDEBBQ27347231-A71DEA9E-48D5-42E5-B118-5314C56F6DA8Q27690715-360336C1-2FF1-42F7-966C-817026FD9F5FQ28084981-20D9AE17-517E-4BEA-BEFA-655D6FCA0DFCQ28477736-5FE04E36-8151-49C1-B2B3-A1CF4653C8C0Q30248286-FE602953-8836-4085-B40B-D5D087B84C19Q30360288-97C95E18-4638-48CC-8142-8965E8690734Q30365593-0E810220-AB50-431F-9CD5-9CB678C2947CQ30397743-D56B6FB7-E769-4059-AB8D-2FEC0A61FDB2Q30532710-9A83AF6C-B24D-49D8-A5B0-B6958A9D8DEEQ30573969-BD232FA0-A8F8-4969-9246-CB034368716AQ30576375-3A76222C-CD2F-4E9B-BD12-E5DA73104415Q30934548-BC4FD806-79C0-471B-9245-CA3195A2F969Q30987054-A4CD877F-5E09-44BA-A81A-E388ED69BCABQ33582629-695F51FB-903B-4F5D-87FB-9331C2B6F359Q33764308-7BE31B8E-2256-4F76-8590-673984AD577EQ33917180-A18C9DC5-5AB7-4703-A706-6B02B849A126Q34036247-D7CC9789-553E-4A3C-AB47-C9F9548045B5Q34477917-1260BDD3-47CF-4A65-BF9F-04DA5B8AF7F4Q34557631-421634DF-7CA3-4BF6-A9CE-2A59591FABA0Q34689241-FC064DBE-F1E7-404A-A36F-903AFC9F522FQ34721127-A09CEBC3-D8D2-48C0-B73F-F74F37BFC066Q34762935-239F3ED8-D58C-4351-8C6E-C045D959C646Q34964855-EF8C4EFE-9968-46EC-9E37-5478C04024AFQ35064091-D8B41BA4-6DC6-43E3-9B52-095CA153B047Q35124939-0CC7CA0D-09C7-4C34-8CA9-BBCEA8293EB1Q35148082-BA0734F5-2494-4E13-9DCF-561129EDDFBDQ35190397-5B9C9DE7-1832-4886-B8C2-252D18337045Q35338096-4955B61F-80D8-43B1-8B5C-1C3176A4A26FQ35453074-C4A9ED53-D9C3-4177-92C4-391790073234Q35643573-32A99E17-6787-4AF8-ADA2-7368E9C152D2Q35644326-6389BB19-12E2-43E3-833A-5BD5409DAFF4Q35730973-97794A0D-D785-4612-A53B-C52BF8E35AF8Q35930402-E27D6D2D-ADD0-485F-A77E-2CF91CB37C83Q35949949-BD067E35-AE1B-4A31-8002-B9D80F6B801FQ35977313-199DA564-71ED-445D-ACB7-572B49DF4B10
P2860
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Predicting the risk of cardiov ...... fects of anti-HIV drugs study.
@ast
Predicting the risk of cardiov ...... fects of anti-HIV drugs study.
@en
type
label
Predicting the risk of cardiov ...... fects of anti-HIV drugs study.
@ast
Predicting the risk of cardiov ...... fects of anti-HIV drugs study.
@en
prefLabel
Predicting the risk of cardiov ...... fects of anti-HIV drugs study.
@ast
Predicting the risk of cardiov ...... fects of anti-HIV drugs study.
@en
P2093
P2860
P50
P1476
Predicting the risk of cardiov ...... fects of anti-HIV drugs study.
@en
P2093
Andrew Phillips
Antonella D'Arminio Monforte
DAD study group
Eric Fontas
Matthew G Law
Nina Friis-Møller
Peter Reiss
Rainer Weber
Signe Worm
P2860
P304
P356
10.1097/HJR.0B013E328336A150
P50
P577
2010-10-01T00:00:00Z